Sections of 30 cases of human cirrhosis were stained with rabbit anti-insulin-likegrowth factor Ⅱ(IGF Ⅱ)by double PAP method.By the serological examination 15 patientsshowed HBV infection and sections of 14 eases we...Sections of 30 cases of human cirrhosis were stained with rabbit anti-insulin-likegrowth factor Ⅱ(IGF Ⅱ)by double PAP method.By the serological examination 15 patientsshowed HBV infection and sections of 14 eases were HBsAg postively with a total rate of 67％(20 cases).The IGF Ⅱ was positive in the cytoplasm of all the liver and ductular cells.Binucle-ated,polypoid liver cells and the peripheral cells of the lobules or nodules were distinctly posi-tive,The liver cells which were strongly positive were a kind of thin polygonal cells with asmall oval or a round deeply stained nucleus in each.They might exist sporadically in the lob-ules or in the marginal portion of a nodule.These liver cells are quite different from the so-called oval cells which are derived from the proliferating ductules and are generally believed tobe responsible for the pathogensis of hepatoma.展开更多
目的探讨^(131)I治疗对分化型甲状腺癌患者术后血清全段甲状旁腺激素(iPTH)、胰岛素样生长因子1(IGF-1)水平的影响。方法回顾性分析河南科技大学第一附属医院2020年1月至2022年9月收治的73例分化型甲状腺癌患者,均接受甲状腺全切除并于...目的探讨^(131)I治疗对分化型甲状腺癌患者术后血清全段甲状旁腺激素(iPTH)、胰岛素样生长因子1(IGF-1)水平的影响。方法回顾性分析河南科技大学第一附属医院2020年1月至2022年9月收治的73例分化型甲状腺癌患者,均接受甲状腺全切除并于术后2个月采用^(131)I治疗,随访1个月根据治疗情况将患者分为有效组(51例)和无效组(22例)。比较两组患者治疗前及治疗7 d iPTH和IGF-1水平,以及有效组治疗后各时间点血清iPTH、IGF-1水平。结果两组患者治疗后7 d血清iPTH、IGF-1水平均低于治疗前,且有效组低于无效组(P<0.05);有效组治疗后不同时间点血清iPTH、IGF-1水平差异有统计学意义(P<0.05)。结论分化型甲状腺癌患者^(131)I治疗后血清iPTH、IGF-1水平变化可用于判断甲状旁腺功能恢复情况,血清iPTH还可预示术后低钙血症的发生。展开更多
基金Supported by the National Natural Science Foundation of China,No.3880376
文摘Sections of 30 cases of human cirrhosis were stained with rabbit anti-insulin-likegrowth factor Ⅱ(IGF Ⅱ)by double PAP method.By the serological examination 15 patientsshowed HBV infection and sections of 14 eases were HBsAg postively with a total rate of 67％(20 cases).The IGF Ⅱ was positive in the cytoplasm of all the liver and ductular cells.Binucle-ated,polypoid liver cells and the peripheral cells of the lobules or nodules were distinctly posi-tive,The liver cells which were strongly positive were a kind of thin polygonal cells with asmall oval or a round deeply stained nucleus in each.They might exist sporadically in the lob-ules or in the marginal portion of a nodule.These liver cells are quite different from the so-called oval cells which are derived from the proliferating ductules and are generally believed tobe responsible for the pathogensis of hepatoma.
文摘目的探讨急性脑梗死(acute cerebral infarction,ACI)患者脑电图、血清胰岛素生长因子1(insulin-like growth factor 1,IGF-1)、神经元特异性烯醇化酶(neuron-specific enolase,NSE)与病灶体积及美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分的关系。方法选择2021年8月至2022年12月在南京市溧水区人民医院神经内科首次确诊的ACI患者218例,根据病灶体积分为大体积组63例、中体积组103例和小体积组52例。检测患者脑电图(δ+θ)与(α+β)功率比[(δ+θ)/(α+β)ratio,DTABR]、大脑对称指数(brainspine interface,BSI)、血清IGF-1和NSE水平,观察上述指标与MRI检查脑梗死病灶体积、NIHSS评分、阿替普酶溶栓后2周、4周时NIHSS评分的相关性。结果中体积组和大体积组IGF-1水平明显低于小体积组,NSE、DTABR、BSI明显高于小体积组(P<0.05);大体积组IGF-1水平明显低于中体积组,NSE、DTABR、BSI明显高于中体积组(P<0.05)。DTABR、BSI、血清NSE与病灶体积(r=0.563,P=0.000;r=0.318,P=0.038;r=0.673,P=0.000)和治疗前NIHSS评分(r=0.499,P=0.000;r=0.362,P=0.013;r=0.750,P=0.001)呈显著正相关。血清IGF-1水平与病灶体积(r=-0.572,P=0.000)和治疗前NIHSS评分(r=-0.438,P=0.001)呈显著负相关。DTABR、BSI、血清NSE、病灶体积均与溶栓后2、4周NIHSS评分呈正相关,IGF-1与溶栓后2、4周NIHSS评分呈负相关(P<0.05,P<0.01)。结论ACI患者脑电图、IGF-1和NSE与病灶体积和溶栓后NIHSS评分显著相关。
文摘目的探讨^(131)I治疗对分化型甲状腺癌患者术后血清全段甲状旁腺激素(iPTH)、胰岛素样生长因子1(IGF-1)水平的影响。方法回顾性分析河南科技大学第一附属医院2020年1月至2022年9月收治的73例分化型甲状腺癌患者,均接受甲状腺全切除并于术后2个月采用^(131)I治疗,随访1个月根据治疗情况将患者分为有效组(51例)和无效组(22例)。比较两组患者治疗前及治疗7 d iPTH和IGF-1水平,以及有效组治疗后各时间点血清iPTH、IGF-1水平。结果两组患者治疗后7 d血清iPTH、IGF-1水平均低于治疗前,且有效组低于无效组(P<0.05);有效组治疗后不同时间点血清iPTH、IGF-1水平差异有统计学意义(P<0.05)。结论分化型甲状腺癌患者^(131)I治疗后血清iPTH、IGF-1水平变化可用于判断甲状旁腺功能恢复情况,血清iPTH还可预示术后低钙血症的发生。
文摘目的探讨不同病因矮小症患儿血清生长激素释放肽(Ghrelin)、胰岛素样生长因子-1(insulinlike growth factor-1,IGF-1)水平变化及其临床意义。方法选取2016年1月至2022年1月南通大学附属医院如皋分院收治的212例矮小症患儿,根据不同病因分为生长激素缺乏症组(n=60)、特发性矮小症组(n=46)、Turner综合征组(n=38)、先天性甲状腺功能减退症组(n=32)和宫内发育迟缓组(n=36),另选取同期于本院行体检证实身高同性别、同年龄标准范围内的106例健康儿童作为对照组。比较不同病因矮小症患儿与对照组的人口学特征和骨龄年龄差(bone age difference,BAD)、身高标准差分值(heightstandard deviation score,Ht SDS)、年生长速率(growth velocity,GV)和生长激素(growth hormone,GH)峰值等生长发育指标及青春前期和青春期的血清Ghrelin、IGF-1水平。采用受试者操作特征(receiveroperating characteristic,ROC)曲线分析血清Ghrelin、IGF-1水平对特发性矮小症的鉴别诊断价值。统计学方法采用单因素方差分析、LSD-t检验及χ^(2)检验。结果特发性矮小症组青春期患儿比例为65.2%,明显高于其他4组(P值均<0.05),其中青春期患儿比例从高至低依次为宫内发育迟缓组(41.7%)、先天性甲状腺功能减退症组(40.6%)、生长激素缺乏症组(35.0%)和Turner综合征组(31.6%);特发性矮小症组BAD为(1.4±0.3)岁,明显高于其他4组(P值均<0.05),其中BAD值从高至低依次为生长激素缺乏症组[(1.2±0.2)岁]、先天性甲状腺功能减退症组[(1.1±0.2)岁]、Turner综合征组[(0.7±0.1)岁]和宫内发育迟缓组[(0.3±0.1)岁]。特发性矮小症组GV值为[(3.7±0.8)cm/年],明显高于其他4组(P值均<0.05),其中GV值从高至低依次为生长激素缺乏症组[(2.2±0.7)cm/年]、宫内发育迟缓组[(2.1±0.6)cm/年]、先天性甲状腺功能减退症组[(1.7±0.5)cm/年]和Turner综合征组[(1.2±0.4)cm/年]。生长激素缺乏症组GH峰值为[(6.4±0.3)μg/L],明显低于其他4组(P值均<0.05),其中GH峰值从低至高依次为宫内发育迟缓组[(13.4±3.2)μg/L]、Turner综合征组[(14.2±2.1)μg/L]、特发性矮小症组[(14.7±2.5)μg/L]和先天性甲状腺功能减退症组[(15.6±2.9)μg/L]。Turner综合征组Ghrelin水平显著高于生长激素缺乏症组、特发性矮小症组、先天性甲状腺功能减退症组和宫内发育迟缓组(P值均<0.05);先天性甲状腺功能减退症组IGF-1水平显著低于生长激素缺乏症组、特发性矮小症组、Turner综合征组和宫内发育迟缓组(P值均<0.05)。特发性矮小症组青春前期的血清Ghrelin、IGF-1水平均明显低于青春期(P值均<0.05)。ROC曲线分析结果显示,血清Ghrelin、IGF-1鉴别诊断特发性矮小症的曲线下面积(area under the curve,AUC)分别为0.776、0.733,联合检测鉴别诊断特发性矮小症的AUC为0.839,灵敏度为90.0%,特异性为65.6%(P<0.001)。结论不同病因矮小症患儿血清Ghrelin、IGF-1水平均存在异常表达,特发性矮小症患儿在青春前期和青春期的血清Ghrelin、IGF-1水平差异明显,血清Ghrelin、IGF-1联合检测对特发性矮小症的鉴别诊断具有较好的诊断效能。
